GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Common Stock

Halberd (Halberd) Common Stock : $0.06 Mil (As of Jul. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Halberd Common Stock?

Halberd's quarterly common stock increased from Jul. 2008 ($0.00 Mil) to Jul. 2022 ($0.05 Mil) and increased from Jul. 2022 ($0.05 Mil) to Jul. 2023 ($0.06 Mil).

Halberd's annual common stock increased from Jul. 2008 ($0.00 Mil) to Jul. 2022 ($0.05 Mil) and increased from Jul. 2022 ($0.05 Mil) to Jul. 2023 ($0.06 Mil).

Halberd Common Stock Historical Data

The historical data trend for Halberd's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Common Stock Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Common Stock
- 0.05 0.06

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Common Stock - 0.05 0.06

Halberd Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Halberd (Halberd) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Common Stock
Comparable Companies
TSSI SWMM SFHI VSR ETOLF ESOA ENG LYOPF BBHDF RCMT LMB CUUHF GV IBIBF LAYN EMFGF LOUIF ORN WLDN GLDD
Traded in Other Exchanges
N/A
Address
P.O. Box 25, Jackson Center, PA, USA, 16133
Website
https://www.halberdcorporation.com
Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
Executives
John Christopher Maddox director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO 10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist director, 10 percent owner, officer: CEO, Secretary and Director 24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr. director 50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas director 280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236